[go: up one dir, main page]

TN2011000100A1 - Galenical formulations of organic compounds - Google Patents

Galenical formulations of organic compounds

Info

Publication number
TN2011000100A1
TN2011000100A1 TN2011000100A TN2011000100A TN2011000100A1 TN 2011000100 A1 TN2011000100 A1 TN 2011000100A1 TN 2011000100 A TN2011000100 A TN 2011000100A TN 2011000100 A TN2011000100 A TN 2011000100A TN 2011000100 A1 TN2011000100 A1 TN 2011000100A1
Authority
TN
Tunisia
Prior art keywords
minutes
dose combination
organic compounds
fixed dose
pharmaceutical oral
Prior art date
Application number
TN2011000100A
Other languages
French (fr)
Inventor
Sudha Vippagunta
Stephen Valazza
Robert Frank Wagner
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2009/057750 external-priority patent/WO2010033954A2/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TN2011000100A1 publication Critical patent/TN2011000100A1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a pharmaceutical oral fixed dose combination comprising a) a therapeutically effective amount of Aliskiren, or a pharmaceutically acceptable salt thereof, b) a therapeutically effective amount of Amlodipine, or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical oral fixed dose combination shows an in vitro dissolution of component (a) of 60% or less after 10 minutes and 98% or less after 20 minutes, and a dissolution profile of component (b) of 50 % or more after 20 minutes, and 70% or more after 30 minutes at pH 2, said pharmaceutical oral fixed dose combination being bioequivalent, or close to reaching bioequivalence, to a free dose combination of Aliskiren and Amlodipine.
TN2011000100A 2009-09-22 2011-02-28 Galenical formulations of organic compounds TN2011000100A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2009/057750 WO2010033954A2 (en) 2008-09-22 2009-09-22 Galenical formulations of organic compounds

Publications (1)

Publication Number Publication Date
TN2011000100A1 true TN2011000100A1 (en) 2012-09-05

Family

ID=55024397

Family Applications (1)

Application Number Title Priority Date Filing Date
TN2011000100A TN2011000100A1 (en) 2009-09-22 2011-02-28 Galenical formulations of organic compounds

Country Status (1)

Country Link
TN (1) TN2011000100A1 (en)

Similar Documents

Publication Publication Date Title
TN2010000135A1 (en) Galenical formulations of organic compounds
PL2205279T3 (en) Pharmaceutical combination of aliskiren and valsartan
SI2046298T1 (en) Pharmaceutical dosage form containing pharmaceutically acceptable solubilizing composition
MX2012007375A (en) 3-keto-n-propargyl-1-aminoindan.
AP2012006231A0 (en) Capsule formulation of pirfenidone and pharmaceutically acceptable excipients.
CO6440564A2 (en) PHARMACEUTICAL COMPOSITIONS OF IMMEDIATE RELEASE THAT INCLUDE OXYCODONE AND NALOXONE
PL2364983T3 (en) Novel tricyclic derivative or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition containing the same
EP2112925A4 (en) Solid pharmaceutical dosage formulations
BRPI1009392A2 (en) "pharmaceutical formulation, and use of a pharmaceutically effective amount of a pharmaceutical formulation."
MX2011007779A (en) Galenic formulations of organic compounds.
UY32749A (en) SOLID PHARMACEUTICAL FIXED DOSAGE COMPOSITIONS INCLUDING IRBESARTAN AND AMLODIPINE, ITS PREPARATION AND THERAPEUTIC APPLICATION
ZA200709788B (en) Cannabinold active pharmaceutical ingredient for Improved dosage forms
MX2007002898A (en) Tablets with site time-controlled gastrointestinal release of active ingredient.
JO3239B1 (en) Galenical Formulations of Organic Compounds
EP2196463A4 (en) Preparation of 5,6-dimethylxanthone-4-acetic acid, the derivatives prepared and pharmaceutical formulations thereof
WO2013098268A3 (en) Tablets and dry-coated agents
WO2010079433A3 (en) Pharmaceutical composition comprising melogliptin
TN2011000100A1 (en) Galenical formulations of organic compounds
CY1113140T1 (en) STRONG ORAL FORM OF THE ORAL, CONTAINING THE ANTI-PETAIL FACTOR, AND A METHOD OF PREPARATION
WO2011161223A3 (en) Pharmaceutical oral dosage forms comprising lercanidipine and enalapril and their pharmaceutically acceptable salts
MX2011009846A (en) Galenical formulations of a fixed dose combination of valsartan and aliskiren.
TW200833375A (en) Pharmaceutical compositions
WO2010044108A3 (en) Controlled release formulations of ropinirole
TH127122A (en) Alis Kyren and Amlodinine Recipes
UA39497U (en) The method for treating systemic lupus erythematosus